KRAS and neoplasm: In order to evaluate whether newly detected KRAS mutations were already present in treatment-naïve primary tumors as undetectable low frequency clones or were truly acquired mutations, the investigators utilized the OncoBEAM RAS assay on the original tumor tissue to re-analyze archival samples from 20 of 27 patients for traces of KRAS clones.